Sign In
Buy LEGN
Legend Biotech Earnings Calls
| Release date | May 12, 2026 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.150 |
| EPS Surprise | -650.00% |
| Revenue estimate | 306.51M |
| Revenue actual | 305.1M |
| Revenue Surprise | -0.460% |
| Release date | Mar 10, 2026 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.0800 |
| EPS Surprise | 52.94% |
| Revenue estimate | 307.756M |
| Revenue actual | 306.3M |
| Revenue Surprise | -0.473% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.110 |
| EPS Surprise | 15.38% |
| Revenue estimate | 309.534M |
| Revenue actual | 272.33M |
| Revenue Surprise | -12.02% |
| Release date | Aug 11, 2025 |
| EPS estimate | -$0.220 |
| EPS actual | -$0.340 |
| EPS Surprise | -54.55% |
| Revenue estimate | 278.193M |
| Revenue actual | 255.955M |
| Revenue Surprise | -7.99% |
Last 4 Quarters for Legend Biotech
Below you can see how LEGN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 11, 2025 |
| Price on release | $36.24 |
| EPS estimate | -$0.220 |
| EPS actual | -$0.340 |
| EPS surprise | -54.55% |
| Date | Price |
|---|---|
| Aug 05, 2025 | $38.42 |
| Aug 06, 2025 | $37.66 |
| Aug 07, 2025 | $37.43 |
| Aug 08, 2025 | $37.00 |
| Aug 11, 2025 | $36.24 |
| Aug 12, 2025 | $36.99 |
| Aug 13, 2025 | $36.93 |
| Aug 14, 2025 | $37.71 |
| Aug 15, 2025 | $37.50 |
| 4 days before | -5.67% |
| 4 days after | 3.48% |
| On release day | 2.07% |
| Change in period | -2.39% |
| Release date | Nov 12, 2025 |
| Price on release | $31.18 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.110 |
| EPS surprise | 15.38% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $32.37 |
| Nov 07, 2025 | $31.80 |
| Nov 10, 2025 | $31.59 |
| Nov 11, 2025 | $32.03 |
| Nov 12, 2025 | $31.18 |
| Nov 13, 2025 | $31.01 |
| Nov 14, 2025 | $30.29 |
| Nov 17, 2025 | $29.72 |
| Nov 18, 2025 | $29.42 |
| 4 days before | -3.69% |
| 4 days after | -5.63% |
| On release day | -0.529% |
| Change in period | -9.11% |
| Release date | Mar 10, 2026 |
| Price on release | $19.56 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.0800 |
| EPS surprise | 52.94% |
| Date | Price |
|---|---|
| Mar 04, 2026 | $17.85 |
| Mar 05, 2026 | $17.75 |
| Mar 06, 2026 | $18.97 |
| Mar 09, 2026 | $19.14 |
| Mar 10, 2026 | $19.56 |
| Mar 11, 2026 | $20.27 |
| Mar 12, 2026 | $19.05 |
| Mar 13, 2026 | $18.75 |
| Mar 16, 2026 | $19.10 |
| 4 days before | 9.58% |
| 4 days after | -2.35% |
| On release day | 3.63% |
| Change in period | 7.00% |
| Release date | May 12, 2026 |
| Price on release | $28.26 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.150 |
| EPS surprise | -650.00% |
| Date | Price |
|---|---|
| May 06, 2026 | $28.96 |
| May 07, 2026 | $28.57 |
| May 08, 2026 | $28.12 |
| May 11, 2026 | $25.58 |
| May 12, 2026 | $28.26 |
| May 13, 2026 | $28.67 |
| May 14, 2026 | $28.60 |
| May 15, 2026 | $27.55 |
| May 18, 2026 | $26.98 |
| 4 days before | -2.42% |
| 4 days after | -4.53% |
| On release day | 1.45% |
| Change in period | -6.84% |
Legend Biotech Earnings Call Transcript Summary of Q1 2026
Legend Biotech reported strong commercial momentum in Q1 2026 driven by CARVYKTI: net trade sales were approximately $597 million, up 52% year-over-year (36% U.S., >200% ex-U.S.), and sequentially up 8% from Q4 2025. Growth drivers include earlier-line penetration (second and third line represented 41% of U.S. apheresis volume vs. 29% a year ago), expanding global footprint (CARVYKTI available in 18 markets and >300 treatment sites), and high manufacturing performance (99% success rate, ~29-day median turnaround, >95% on-time order releases). Management highlighted ongoing manufacturing capacity expansion (temporary margin impact in Q1 from Raritan/Tech Lane ramp) with gross margin expected to rebound above 50% in Q2. Pipeline progress: pivotal Phase III CARTITUDE-5 and CARTITUDE-6 are fully enrolled and event-driven (data expected in 2026–2027 timeframe); several In Vivo CAR-T programs have entered Phase I including a CD19/CD20 program (LB2501) in NHL with potential data presentation midyear, and a BCMA In Vivo program in autoimmune disease. Financials: adjusted net loss narrowed to $11 million in Q1; collaboration revenue of ~$298 million and total revenue of ~$305 million; ending cash ~ $835 million and no long-term debt. Management reiterates confidence in achieving company-wide adjusted profitability in 2026 while continuing targeted R&D investment in next-generation and In Vivo platforms.
